Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Linezolid.

D Clemett1, A Markham

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|May 10, 2000
PubMed
Summary
This summary is machine-generated.

Linezolid, an oxazolidinone antibiotic, effectively treats gram-positive bacterial infections by inhibiting protein synthesis. Clinical trials show high success rates for skin, pneumonia, and resistant enterococcal infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cabotegravir Plus Rilpivirine: First Approval.

Drugs·2020
Same author

Benralizumab: First Global Approval.

Drugs·2018
Same author

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs·2016
Same author

Erratum to: Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease.

CNS drugs·2016
Same author

Erratum to: Ziprasidone.

CNS drugs·2016
Same author

Obeticholic Acid: First Global Approval.

Drugs·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Linezolid is an oxazolidinone antibacterial agent.
  • It inhibits bacterial protein synthesis initiation.
  • No cross-resistance with other protein synthesis inhibitors has been observed.

Purpose of the Study:

  • To evaluate the efficacy and safety of linezolid.
  • To assess its activity against various gram-positive pathogens.
  • To compare linezolid with vancomycin in specific infections.

Main Methods:

  • Review of linezolid's spectrum of activity.
  • Analysis of clinical trial data for skin/soft tissue infections and pneumonia.
  • Evaluation of treatment outcomes in vancomycin-resistant enterococcal infections.

Related Experiment Videos

Main Results:

  • Linezolid demonstrates broad-spectrum activity against resistant gram-positive organisms, including MRSA and VRE.
  • High clinical success rates observed in skin/soft tissue infections (>83%) and community-acquired pneumonia (>94%).
  • Linezolid shows comparable efficacy to vancomycin in hospital-acquired pneumonia and MRSA infections, with >85% cure rates in VRE infections.

Conclusions:

  • Linezolid is an effective treatment option for various gram-positive bacterial infections, including those caused by resistant strains.
  • It is generally well-tolerated, with gastrointestinal disturbances being the most common adverse events.
  • No evidence of monoamine oxidase inhibition-related adverse reactions has been reported in clinical trials.